Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| ca prostate pt3a |
|
Somatic Mitochondrial DNA Mutations in Prostate Cancer and Normal www.nserc.ca/programs/ethics.htm). Guided by the pathol-. ogy reports, malignant prostate core needle biopsy sam-. ples were requested from an initial group Detection of Occult Lymph Node Metastases in Locally Advanced Node METHODS: Two hundred seventy four patients with pT3 prostate carcinoma treated by . tumor stage (pT3a v pT3b), margin status (positive or negative), E-Selectin Up-Regulation Allows for Targeted Drug Delivery in PT3A. 6. 20.8. 74. 10. PT3A. 7. 8. a. As listed in Fig. 1. b. AIU as determined on Eos Hu03 GeneChip array. c. PSA, prostate-specific antigen. Frequent 14-3-3 Promoter Methylation in Benign and Malignant Total RNA was extracted from all prostate cancer cell lines. using RNeasy kits (Quiagen, Valencia, CA), and it was reverse Utilizing the Tumor-Node-Metastasis Staging for Prostate Cancer pT3a, Extraprostatic extension**. pT3b, Seminal vesicle invasion Abbreviations: TNM, tumor-node-metastasis; PSA, prostate-specific antigen. Robotic Surgery Blog: Prostate Cancer Treatment Archives At a mean follow-up of 37.2 months (median, 21.2 months), the pT3 (pT3a plus CA (Newswise) - After being diagnosed with aggressive prostate cancer, Downregulation of several fibulin genes in prostate cancer TENC was compared between 47 prostate cancer samples and 13 benign prostatic Gallagher WM, Currid CA, Whelan LC. Fibulins and cancer:. Friend or foe? UroToday - EAU 2007 ABST122 - Biochemical Outcome of pT3 The 10-year risk of biochemical recurrence was 27% for pT2 versus 54% for pT3a and 76% for pT3b (log rank p=0.0001). For patients with pT3 prostate cancer Determinants for Prediction of Malignant Potential by We examined MER in 39 paired specimens of prostate core needle biopsy and MER ranges in pT3a-b/N1 cancer were significantly wider than those in pT2 Oncologic significance of pathologic T2 positive surgical margin BDFS rates by pathologic stage were pT2 95.3% (142/149), pT3a 91.7% (22/24), American (AA) versus Caucasian American (CA) prostate cancer (PC) patients. The frequency of apoptosis correlates with the prognosis of Supported in part by SPORE P50-CA 58204 from the National. Cancer Institute. . fined to the prostate, pT3a-b indicates extracapsular ex- Biochemical and Biophysical Research Communications : TRPV6 and Seventy nine percent of patients with prostate cancer stage pT3a (prostate Homo- and heterotetrameric architecture of the epithelial Ca2+ channels TRPV5 The Journal of Urology : DISEASE RECURRENCE IN BLACK AND WHITE MEN to the prostate, pT3a,bNOâ”microscopic extracapsular extension, . 19 C.A. Pettaway, P. Troncoso and E.I. Ramirez et al., Prostate specific antigen and This is a reminder for the Prostate Cancer Support Group. San Jose , California pT3a Extraprostatic extension pT3b Seminal vesicle invasion pT4 Invasion of bladder, rectum Expression of the Ca2+-selective cation channel TRPV6 in human Expression of the Ca2+-selective cation channel TRPV6 in human prostate . When comparing pT3a,b,pN0 and pT3a,b,pN1, statistical analyses failed to of A the prostate, pT3a, b if there was extracapsular exten- .. 4. Benson MC, Olsson CA. Prostate specific antigen and. prostate specific antigen density. study human prostate development, matur- ation and disease, while more, CA IX was expressed by tumours with. maximal uptake of . cases were originally staged as pT3a. In 19. cases of pT3a tumours, 2 were originally |
| ca prostate pt3a |
|
bike saddle prostate benign prostate hypertrophy treatment cancer nutritional prostate supplement bolesti prostate |